Literature DB >> 11026693

Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion.

B Frankel1, S L Longo, G W Canute.   

Abstract

Gliomas of all grades have been shown to express FasL, an apoptosis-inducing protein. Because of the ability of FasL to be cleaved from cell surfaces by metalloproteinases, soluble FasL can be released by FasL bearing cells into surrounding tissues. In the present study, we demonstrate the presence of sFasL in the cyst fluids of astrocytomas. Additionally, a human T-cell line, Jurkat, exposed to astrocytoma cyst fluid resulted in significantly increased cytotoxicity as compared to controls, an effect blocked by FasL neutralizing antibodies. This suggests that sFasL, may be utilized as a means of escaping immune surveillance by these tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11026693     DOI: 10.1023/a:1006473800589

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

2.  Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors.

Authors:  C Gratas; Y Tohma; E G Van Meir; M Klein; M Tenan; N Ishii; O Tachibana; P Kleihues; H Ohgaki
Journal:  Brain Pathol       Date:  1997-07       Impact factor: 6.508

3.  Detectable concentrations of Fas ligand in cerebrospinal fluid after severe head injury.

Authors:  W Ertel; M Keel; R Stocker; H G Imhof; M Leist; U Steckholzer; M Tanaka; O Trentz; S Nagata
Journal:  J Neuroimmunol       Date:  1997-12       Impact factor: 3.478

4.  Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

Authors:  S Strand; W J Hofmann; H Hug; M Müller; G Otto; D Strand; S M Mariani; W Stremmel; P H Krammer; P R Galle
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

5.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

Authors:  P Saas; P R Walker; M Hahne; A L Quiquerez; V Schnuriger; G Perrin; L French; E G Van Meir; N de Tribolet; J Tschopp; P Y Dietrich
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

6.  Transforming growth factor-beta 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression.

Authors:  M Weller; D B Constam; U Malipiero; A Fontana
Journal:  Eur J Immunol       Date:  1994-06       Impact factor: 5.532

7.  Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells.

Authors:  F Leithäuser; J Dhein; G Mechtersheimer; K Koretz; S Brüderlein; C Henne; A Schmidt; K M Debatin; P H Krammer; P Möller
Journal:  Lab Invest       Date:  1993-10       Impact factor: 5.662

8.  Activated B cells express functional Fas ligand.

Authors:  M Hahne; T Renno; M Schroeter; M Irmler; L French; T Bornard; H R MacDonald; J Tschopp
Journal:  Eur J Immunol       Date:  1996-03       Impact factor: 5.532

9.  Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.

Authors:  J H Kehrl; A B Roberts; L M Wakefield; S Jakowlew; M B Sporn; A S Fauci
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

10.  Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

Authors:  P A Ruffini; L Rivoltini; A Silvani; A Boiardi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

View more
  2 in total

Review 1.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

2.  Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo.

Authors:  Timothy F Witham; Lorissa Villa; Tianbing Yang; Ian F Pollack; Hideho Okada; Paul D Robbins; William H Chambers
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.